Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells
In the authors' words
Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD28 CAR T cells match anti‑CD7 CAR T cells in vitro and in vivo, but cause markedly less lymphodepletion, largely sparing CD8 T cells and NK cells while preferentially depleting CD4 T cells, particularly TH2 and TH17 subsets. These findings establish CD28 as an actionable target for CAR T cell therapy of T cell malignancies.
In plain words AI summary
No immunotherapy is currently approved for T cell acute lymphoblastic leukemia. CD28 is overexpressed on cancer cells from young patients with this leukemia. The researchers made CAR T cells that target CD28 and tested them in lab dishes and living organisms. These CAR T cells worked as well as existing anti-CD7 CAR T cells but caused less depletion of immune cells. The findings establish CD28 as a target for treating T cell cancers with CAR T cell therapy.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Saturday, October 10. Nature Communications. Peer-reviewed journal.